Drug Information

Drug Interaction:

MAOI s- Concomittant serotonin precursors eg tryptophen, serotonergics eg triptans, tramadol not recomended

Avoid IV digoxin ( postural hypotension ) tachycardia

May potentiate anticoagulants eg asiprin, NSAIDs , coumarin

May antagonise certain antihypertensives eg clonidine Serotonin syndrome with SSRIs , SNRIs, lithium, tramadol, triptans ( monitor )

Caution with certain other CNS active drugs or those can increase BP. Arrhythmias, hypertension with epinephrine, norepinephrine

Indication:

U.S.FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08

Drug name Indication Date of Approval

137. Milnacipran Hcl 25mg/50mg equivalent to 22-05-08

Milnacripran free base 21.77 or 43.55 mg tablet

For the treatment of adult patients with major

depressive disorder

Proprietary Name- Savella tablets

Established Name - Milnacipran Hcl

Applicant- Cypress Bioscience INC

Indication-

Management of Fibromyalgia

Approved by FDA on 14-1-2009 (Ref- FDA approved List- 2009)

Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)

Name of Drug Indication Date of Approval

1.Milnacipran 100mg 16-03-2010
Addtnl. Stgth

Same as approved

2.Milnacipran 25/50mg caps 15-04-2009
Addl.Indcn.

For the management of Fibromylagia

3.Milnacipran Hcl 12.5mg 06-02-2010
Addl.Stgth

same as approved

4.Milnacipran Hcl 25mg/50mg 22-05-2008
equiv.to Milnacipran Free base

21.77 or 43.55mg tablet

For the treatment of adult patients with major depressive disorder

Fibromyalgia

Adverse Reaction:

GI upset, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, palpitations, increased heart rate dry mouth, hypertension seratonin syndrome- (agitation, hallucinations, tschcardia, labile blood pressure hyperthermia, incordination, nausea, vomiting, diarrheoa )

Neuroleptic syndrome NMS like reactions.

Rarely- GU effects in men hyponatraemia ( esp in elderly ) seizures

Contra-Indications:

Allow at least 14 days after MAOI discontinuation before starting milnacipran Allow at least 5 days after discontinuing minacripran before starting MAOIs Uncontrolled narrow angle glaucoma, End stage renal disease Lactation

Special precautions-

substantial alcohol abuse, chronic liver disease .

Hypertension heart disease monitor BP and heart rate reduce dose or discontinue if elevated BP persists

controlled narrow angle glaucoma seizure disorder- suicidal ideation ( monitor ) mania severe hepatic dysfunction discontinue if liver dysfunction develops volume depleted GU obstruction

Risk of bleeding reevaluate peridically labour and delivery- pregnancy - effects foetus

Dosages/ Overdosage Etc:

Fibromyalgia

Dosage-

Day 1 12.5mg once Day 2-3 12.5mg twice Days 4 -7 25mg twice daily

After Day 7 50mg twice daily ( recommended dose )

Max 100mg twice daily Severe renal impairment - CrCl 5 - 29m/L

Maintenance - 25mg twice daily Max 50mg twice daily

Withdraw gradually

Children below 17 yrs not recommended

Pregnancy and lactation:

Oberve caution if use is required during pregnancy and lactation

Milnacipran Hcl- Serotinin and Norepinephrine reuptake Inhibitors- Antidepressants -(May 2008)

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Pregnancy and lactation

Drug Interaction:

Indication:

Adverse Reaction:

Contra-Indications:

Dosages/ Overdosage Etc:

Pregnancy and lactation:

Search

Quick Links

Free Mobile App

	Starts With		Contains